Christopher Janus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christopher Janus has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
David Westaway
3 shared publications- Peter St George-Hyslop
Department of Neurology, Columbia University Irving Medical Center, New York, USA
2 shared publications Amanda Hanna
1 shared publicationAzhar Chishti
Centre for Research in Neurodegenerative Diseases, 6 Queen's Park Cr. W., Toronto, Ontario, Canada M5S 3H2
1 shared publicationCatherine Bergeron
Centre for Research in Neurodegenerative Diseases, 6 Queen's Park Cr. W., Toronto, Ontario, Canada M5S 3H2
1 shared publicationD Westaway
1 shared publication
Latest Publications
- 1 October 2004
- Published by Elsevier in Neurobiology of Aging
- Vol. 25 (9) , 1213-1219
Impaired conditioned taste aversion learning in APP transgenic mice
- 1 October 2004
- Published by Elsevier in Neurobiology of Aging
- Vol. 25 (9) , 1213-1219
Impaired conditioned taste aversion learning in APP transgenic mice
- Open Access
- 28 May 2004
- Published by Cold Spring Harbor Laboratory in Learning & Memory
- Vol. 11 (3) , 337-346
Search Strategies Used byAPPTransgenic Mice During Navigation in the Morris Water Maze
TgCRND8 mice represent a transgenic mouse model of Alzheimer's disease, with onset of cognitive impairment and increasing amyloid-β plaques in their brains at 12 weeks of age. In this study, the spatial memory in 25- to 30-week-old TgCRND8 mice was analyzed in two reference and one working memory Morris water maze (MWM) tests. In reference memory tests, the mice were trained to escape to a hidden platform, which in one version of the test was marked by a visual cue. In the working memory test, the hidden platform was moved daily to different locations. The TgCRND8 mice were impaired in reference memory when trained in a hidden platform test. However, the mice developed spatial memory comparable to non-Tg littermates in a cued reference memory test. The mice showed also an impairment in spatial working memory. Analysis of search paths revealed that in contrast to non-Tg littermates, TgCRND8 mice did not use spatial strategies during their navigation. Instead, they learned to locate an escape platform using a nonspatial, chaining strategy. The study showed that (1) the impairment in the reference memory of TgCRND8 mice was reduced when a hidden platform was cued, and that (2) both working and reference memory systems of TgCRND8 mice, but not (3) the plasticity of choice between search strategies, are compromised by the transgene-induced pathology.
- 28 May 2004
- Published by Cold Spring Harbor Laboratory in Learning & Memory
- Vol. 11 (3) , 337-346
Open AccessSearch Strategies Used byAPPTransgenic Mice During Navigation in the Morris Water Maze
TgCRND8 mice represent a transgenic mouse model of Alzheimer's disease, with onset of cognitive impairment and increasing amyloid-β plaques in their brains at 12 weeks of age. In this study, the spatial memory in 25- to 30-week-old TgCRND8 mice was analyzed in two reference and one working memory Morris water maze (MWM) tests. In reference memory tests, the mice were trained to escape to a hidden platform, which in one version of the test was marked by a visual cue. In the working memory test, the hidden platform was moved daily to different locations. The TgCRND8 mice were impaired in reference memory when trained in a hidden platform test. However, the mice developed spatial memory comparable to non-Tg littermates in a cued reference memory test. The mice showed also an impairment in spatial working memory. Analysis of search paths revealed that in contrast to non-Tg littermates, TgCRND8 mice did not use spatial strategies during their navigation. Instead, they learned to locate an escape platform using a nonspatial, chaining strategy. The study showed that (1) the impairment in the reference memory of TgCRND8 mice was reduced when a hidden platform was cued, and that (2) both working and reference memory systems of TgCRND8 mice, but not (3) the plasticity of choice between search strategies, are compromised by the transgene-induced pathology.
- Open Access
- 31 January 2003
- Published by Wiley in Genes, Brain and Behavior
- Vol. 2 (1) , 56-61
Modeling behavior: the quest to link mechanisms to function
T. Dobzhansky (1973) has been credited with saying: 'nothing in biology makes sense, except in the light of evolution'. The evolutionary conservation of gene function, as well as remarkable conservation of elemental behavioral mechanisms, guarantees that much of what we learn in one organism will inform our understanding of behavior in all animals, including humans. This insight has permitted behavior-geneticists to choose organisms based on experimental tractability for a given scientific question. IBANGS as a society has clearly embraced this Dobzhanskian worldview. As a result, the intellectual synergy of cross-species behavior-genetic analysis was palpable at the IBANGS meeting in Tours, France.
- 31 January 2003
- Published by Wiley in Genes, Brain and Behavior
- Vol. 2 (1) , 56-61
Open AccessModeling behavior: the quest to link mechanisms to function
T. Dobzhansky (1973) has been credited with saying: 'nothing in biology makes sense, except in the light of evolution'. The evolutionary conservation of gene function, as well as remarkable conservation of elemental behavioral mechanisms, guarantees that much of what we learn in one organism will inform our understanding of behavior in all animals, including humans. This insight has permitted behavior-geneticists to choose organisms based on experimental tractability for a given scientific question. IBANGS as a society has clearly embraced this Dobzhanskian worldview. As a result, the intellectual synergy of cross-species behavior-genetic analysis was palpable at the IBANGS meeting in Tours, France.
- 1 January 2003
- Published by Springer Nature in CNS Drugs
- Vol. 17 (7) , 457-474
Vaccines for Alzheimer??s Disease
Alzheimer’s disease is a neurodegenerative disorder characterised by a progressive loss of cognitive function. Despite the considerable progress being made, a complete description of the molecular pathology of this disease has yet to be elucidated. The evidence indicates that abnormal processing and extracellular deposition of the longer form of the β-amyloid (Aβ) peptide (Aβ1-42, a proteolytic derivative of the amyloid precursor protein [APP]) is implicated in the pathogenesis of Alzheimer’s disease. In this respect, recent use of experimental mouse models, in which the mice develop some aspects of Alzheimer’s disease in a reproducible fashion, has provided a new opportunity for a multidisciplinary and invasive analysis of mechanisms behind the amyloid pathology and its role in Alzheimer’s disease. It has been demonstrated, using a single transgenic mouse model system that overexpresses the human mutated APP gene, that an immunisation against Aβ1-42 causes a marked reduction in the amyloid burden in the brain. The follow-up research provided more evidence that both active and passive Aβ immunisation also reduces cognitive dysfunction in transgenic mouse models of Alzheimer’s disease. Other studies using different approaches — such as secretase, cholesterol and Aβ metalloprotein inhibitors or NSAIDs — but all targeting the abnormal metabolism of Aβ have confirmed in each case that a significant reduction of amyloid plaque burden can be achieved in transgenic mouse models of Alzheimer’s disease. This research strongly supports the notion that abnormal Aβ processing is essential to the pathogenesis of Alzheimer’s disease and provides a crucial platform for the development and detailed testing of potential treatments in experimental models before each of these approaches can be proposed as a therapy for Alzheimer’s disease. Although the first clinical trial of active immunisation with a pre-aggregated synthetic Aβ42 preparation (AN-1792 vaccine) met with some setbacks and was discontinued after several patients experienced meningoencephalitis, the follow-up analysis of the effect of immunisation against Aβ in humans revealed a powerful effect of vaccination in the clearance of amyloid plaques from the cerebral cortex.
- 1 January 2003
- Published by Springer Nature in CNS Drugs
- Vol. 17 (7) , 457-474
Vaccines for Alzheimer??s Disease
Alzheimer’s disease is a neurodegenerative disorder characterised by a progressive loss of cognitive function. Despite the considerable progress being made, a complete description of the molecular pathology of this disease has yet to be elucidated. The evidence indicates that abnormal processing and extracellular deposition of the longer form of the β-amyloid (Aβ) peptide (Aβ1-42, a proteolytic derivative of the amyloid precursor protein [APP]) is implicated in the pathogenesis of Alzheimer’s disease. In this respect, recent use of experimental mouse models, in which the mice develop some aspects of Alzheimer’s disease in a reproducible fashion, has provided a new opportunity for a multidisciplinary and invasive analysis of mechanisms behind the amyloid pathology and its role in Alzheimer’s disease. It has been demonstrated, using a single transgenic mouse model system that overexpresses the human mutated APP gene, that an immunisation against Aβ1-42 causes a marked reduction in the amyloid burden in the brain. The follow-up research provided more evidence that both active and passive Aβ immunisation also reduces cognitive dysfunction in transgenic mouse models of Alzheimer’s disease. Other studies using different approaches — such as secretase, cholesterol and Aβ metalloprotein inhibitors or NSAIDs — but all targeting the abnormal metabolism of Aβ have confirmed in each case that a significant reduction of amyloid plaque burden can be achieved in transgenic mouse models of Alzheimer’s disease. This research strongly supports the notion that abnormal Aβ processing is essential to the pathogenesis of Alzheimer’s disease and provides a crucial platform for the development and detailed testing of potential treatments in experimental models before each of these approaches can be proposed as a therapy for Alzheimer’s disease. Although the first clinical trial of active immunisation with a pre-aggregated synthetic Aβ42 preparation (AN-1792 vaccine) met with some setbacks and was discontinued after several patients experienced meningoencephalitis, the follow-up analysis of the effect of immunisation against Aβ in humans revealed a powerful effect of vaccination in the clearance of amyloid plaques from the cerebral cortex.
- 1 August 2001
- Published by Elsevier in Physiology & Behavior
- Vol. 73 (5) , 873-886
Transgenic mouse models of Alzheimer's disease
- 1 August 2001
- Published by Elsevier in Physiology & Behavior
- Vol. 73 (5) , 873-886
Transgenic mouse models of Alzheimer's disease
- 28 March 2001
- Published by Wiley
- p. 697-704
Changes in Cognitive Characteristics of Tg(APP)CRND8 Mice at Early Stages of Immunization with Beta‐Amyloid Peptide
- 28 March 2001
- Published by Wiley
- p. 697-704
Changes in Cognitive Characteristics of Tg(APP)CRND8 Mice at Early Stages of Immunization with Beta‐Amyloid Peptide
- 1 July 2000
- Published by Elsevier in Neurobiology of Aging
- Vol. 21 (4) , 541-549
Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes
- 1 July 2000
- Published by Elsevier in Neurobiology of Aging
- Vol. 21 (4) , 541-549
Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes